Director/PDMR Shareholding

AstraZeneca PLC
02 May 2006


Dealing by Directors
Companies Act 1985 Sections 324/329


We hereby inform you that the interest of David R Brennan, a Director of the
Company, in the American Depositary Shares (ADSs) of AstraZeneca PLC has changed
as detailed below.  One ADS equals one Ordinary Share.

As previously notified on 28 March 2006, Mr Brennan became unconditionally
entitled to 31,780 ADSs on the partial vesting of an award under the terms of
the AstraZeneca US Executive Performance Share Plan.  At that time, Mr Brennan
elected to defer the value of those ADSs, less certain mandatory tax deductions,
into the AstraZeneca US Executive Deferred Compensation Plan, a unitised stock
fund in which Mr Brennan, in common with other participating US executives, is
deemed to have a notional interest in ADSs calculated by reference to the fund
value and the closing price of AstraZeneca ADSs.  This deferral occurred
automatically on 28 April 2006, following which Mr Brennan has a notional
interest in 28,831 ADSs in the AstraZeneca US Executive Deferral Plan as at 28
April 2006 based on that day's closing price of US$55.13.

In total, Mr Brennan now has an interest in 167,453 AstraZeneca ADSs and 79,461
Ordinary Shares, including the notional interest in ADSs in the AstraZeneca US
Executive Deferred Compensation Plan referred to above.


G H R Musker
Company Secretary
2 May 2006



                      This information is provided by RNS
            The company news service from the London Stock Exchange     
RDSUUVVRNNRVRAR